Abstract: Novel chromogenic, fluorogenic and fluorescence polarization substrates which are useful in HCV NS3 protease and inhibitor assays.

Abstract: Monoclonal antibodies are provided which are specific for human interleukin-4. Kits and methods are also provided for detecting, measuring and immunopurifying human interleukin-4.

Abstract: Monoclonal antibodies are provided which are specific for human interleukin-4. Kits and methods are also provided for detecting, measuring and immunopurifying human interleukin-4, and for blocking the biological activity of human interleukin-4.

Abstract: The present invention pertains to a method for non-specifically enhancing the immune system response of a mammal to an antigen which comprises the steps of (a) withdrawing leukocyte containing material from the mammal, (b) treating the withdrawn leukocytes in a manner to alter the cells, and (c) returning the treated leukocytes to the mammal. In one embodiment, the method for non-specifically enhancing the immune system response of a mammal is carried out in conjunction with artificially contacting the mammal's immune system with an antigen for a suitable period of time to stimulate the immune system. In another embodiment, the mammal's immune system is naturally exposed to the antigen prior to the non-specific enhancement of the immune system. In yet another embodiment, the invention is directed at a method for preparing an autologous non-specific leukocyte adjuvant.

Abstract: The present invention pertains to a method for non-specifically enhancing the immune system response of a mammal to an antigen which comprises the steps of (a) withdrawing leukocyte containing material from the mammal, (b) treating the withdrawn leukocytes in a manner to alter the cella, and (c) returning the treated leukocytes to the mammal. The one embodiment, the method for non-specifically enhancing the immune system response of a mammal is carried out in conjunction with artificially contacting the mammal's immune system with an antigen for a suitable period of time to stimulate the immune system. In another embodiment, the mannal's immune system is naturally exposed to the antigen prior to the non-specific enhancement of the immune system. In yet another embodiment, the invention is directed at a method for preparing an autologous non-specific leukocyte adjuvant.

Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically effective amount of human epidermal growth factor (EGF) and an amount of a pharmaceutically acceptable metal cation, such as zinc, which is sufficient to prevent the degradation of said EGF.

Abstract: The present invention provides acylated epidermal growth factor derivatives, methods of making the derivatives and pharmaceutical compositions containing the derivatives.

Abstract: A method is provided for preventing tissue damage in a patient after the tissue has been deprived of blood supply resulting in ischemia. The method involves administering to the patient a polypeptide having epidermal growth factor activity or fibroblast growth factor activity prior to or after the ischemic event.

Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on normal human monocytes and granulocytes. The hybrid is formed by fusing splenocytes from immunized BALB/cJ mice with P3X63Ag8Ul myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: Authentication and verification of suitability for use of disposable elements can be made by evaluation of characteristic data stored on a non-volatile read/write memory element, especially useful in a photoactivatable agent patient treatment system wherein photoactivatable agents, in contact with patient blood cells, are irradiated extracorporeally and then returned to the patient.

Abstract: A method is provided for discriminating white blood cells from red blood cells and platelets in an unlysed, whole blood sample. The white blood cells may be discriminated into five subpopulations: lymphocytes, monocytes, neutrophils, eosinophils and basophils. A red light absorbing fluorescent dye is utilized along with a measurement system comprised of a red light source and suitable detectors for red fluorescence, forward light scatter and right angle scatter.

Abstract: A method is provided for specifically altering the immune system response of a mammal to a specific antigen. The method comprises the steps of: (a) contacting the mammal's immune system with the specific antigen for a suitable time period so as to artificially stimulate said immune system; (b) withdrawing blood cell containing material, including antigen stimulated blood cells, from the mammal; (c) treating the withdrawn material or cells so as to alter the stimulated cells; and (d) returning the material and treated cells to the mammal.

Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: Methods for attaching one component of a ligand-anti-ligand pair onto a solid phase surface. The component may be attached to a photoactivatable cross-linker capable of coupling the component to a colloidal medium coating the surface or alternatively, the component may be coupled to a bead and held in place against the surface by an overlay of the colloidal media having voids and spaces smaller than the diameter of the particle but large enough to permit diffusion of the other of the ligand-anti-ligand pair to be detected.

Abstract: A method for treating allergy by administration of the peptide thymopentin.

Abstract: A method is provided for substantially increasing the dynamic range of an immunoassay and forestalling the hook effect observed with very large ligand concentrations in aqueous samples. The method comprises the addition of ligand binding partners which do not have labels associated therewith to compete with labeled ligand binding partners thereby effectively eliminating the presence of the excess ligand in the sample solution. The conversant method for ligand binding partner immunoassays is also provided.

Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: A removable U.V. light array assembly for use in a photoactivatable agent, patient treatment system wherein photoactivatable agents, in contact with patient blood cells, are irradiated extracorporeally and then returned to the patient.

Abstract: A method of seriatim administration to a patient of a plurality of ligands, each of which contains an antigen combining site of a monoclonal antibody of distinct idiotype, is disclosed. This method is useful for therapeutic as well as diagnostic purposes.

Abstract: A stable mutant human T cell line is disclosed which secretes a high titer suppressor inducer factor. This suppressor inducer factor in turn induces production of a T cell suppressor factor which suppressed mitogen-induced T cell proliferation at high dilution. Also disclosed is a general method for mutating lymphoblastoid cell lines to yield mutants secreting enhanced levels of lymphokines.